About the job
Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on areas where current treatments fall short. The company’s neuroscience portfolio includes FDA-approved medications for major depressive disorder, excessive daytime sleepiness related to narcolepsy and obstructive sleep apnea, and migraine.
Ongoing late-stage development programs address a broad range of neurological and psychiatric conditions that impact more than 150 million people in the United States. Axsome’s work centers on advancing new approaches to improve patient outcomes and quality of life.
What sets Axsome apart
- Focus on CNS disorders and brain health
- Development of therapies with novel mechanisms of action
- Commitment to addressing critical gaps in patient care
The team’s goal is to help patients and families manage serious conditions and thrive.
